Extended Data Fig. 1: Extended Clinical Data.
From: IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
(a) Details of patient cohort, tests are as specified and were two-sided (b) Comparative response of lymphocyte count to cICB and sICB; two-sided Wilcoxon signed rank test, n = 134 patients (74 cICB, 60 sICB). c) Comparison of fall in lymphocyte count in recipients of nivolumab versus those of pembrolizumab; two-sided T tests (n = 74 ipi/nivo, n = 9 nivo, n = 51 pembrolizumab). (d) Kaplan Meier analysis of progression-free survival in immunotherapy naïve metastatic melanoma patients within the cohort according to LS (unstable defined as post-treatment lymphocyte count ≤80% pre-treatment value); log-rank test (n = 111). (e) As per (d), but curves represent overall survival across cohort according to LS (n = 111). For boxplots in Extended Data Fig. 1b, c central line reflects the median, the box reflects the 25%–75% quartiles, upper whisker extends to largest value no further than 1.5x interquartile range, lower whisker extends from 25% quartile to the smallest value no further than 1.5x interquartile range.
